The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
Open Access
- 1 August 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Targeted Oncology
- Vol. 10 (2), 235-245
- https://doi.org/10.1007/s11523-014-0329-6
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsInvestigational New Drugs, 2012
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?Clinical Cancer Research, 2012
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesTherapeutic Advances in Medical Oncology, 2011
- Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing RegimensThe Oncologist, 2010
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor ResistanceCancer Research, 2008
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005